A dose range finding study of PTI-NC-733 (fixed dose combination PTI-808, PTI-428 and PTI-801)
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs PTI NC 733 (Primary) ; PTI 808
- Indications Cystic fibrosis
- Focus Adverse reactions; Proof of concept
- 14 Nov 2017 According to a Proteostasis Therapeutics media release, the company expects to initiate this trial in the first half of 2018.
- 04 Jul 2017 New trial record
- 29 Jun 2017 This trial is expected to begin in the end of 2017, according to a Proteostasis Therapeutics media release.